Nonalcoholic fatty liver disease: An emerging threat to obese and diabetic individuals

Research output: Contribution to journalArticle

137 Citations (Scopus)

Abstract

Nonalcoholic fatty liver disease (NAFLD) is the most common liver disease in the Western world and its incidence is increasing rapidly. NAFLD is a spectrum ranging from simple steatosis, which is relatively benign hepatically, to nonalcoholic steatohepatitis (NASH), which can progress to cirrhosis. Obesity, insulin resistance, type 2 diabetes mellitus, and dyslipidemia are the most important risk factors for NAFLD. Due to heavy enrichment with metabolic risk factors, individuals with NAFLD are at significantly higher risk for cardiovascular disease. Individuals with NAFLD have higher incidence of type 2 diabetes. The diagnosis of NAFLD requires imaging evidence of hepatic steatosis in the absence of competing etiologies including significant alcohol consumption. Liver biopsy remains the gold standard for diagnosing NASH and for determining prognosis. Weight loss remains a cornerstone of treatment. Weight loss of ∼5% is believed to improve steatosis, whereas ∼10% weight loss is necessary to improve steatohepatitis. A number of pharmacologic therapies have been investigated to treat NASH, and agents such as vitamin E and thiazolidinediones have shown promise in select patient subgroups.

Original languageEnglish
Pages (from-to)106-122
Number of pages17
JournalAnnals of the New York Academy of Sciences
Volume1281
Issue number1
DOIs
StatePublished - Apr 2013

Fingerprint

Liver
Weight Loss
Medical problems
Type 2 Diabetes Mellitus
Thiazolidinediones
Non-alcoholic Fatty Liver Disease
Threat
Biopsy
Western World
Vitamin E
Incidence
Fatty Liver
Dyslipidemias
Alcohol Drinking
Insulin Resistance
Liver Diseases
Alcohols
Fibrosis
Cardiovascular Diseases
Insulin

Keywords

  • Fatty liver
  • Steatohepatitis
  • Steatosis
  • Thiazolidinediones

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • History and Philosophy of Science

Cite this

@article{1aa18e3c42204a0f89d534ba570b7cfd,
title = "Nonalcoholic fatty liver disease: An emerging threat to obese and diabetic individuals",
abstract = "Nonalcoholic fatty liver disease (NAFLD) is the most common liver disease in the Western world and its incidence is increasing rapidly. NAFLD is a spectrum ranging from simple steatosis, which is relatively benign hepatically, to nonalcoholic steatohepatitis (NASH), which can progress to cirrhosis. Obesity, insulin resistance, type 2 diabetes mellitus, and dyslipidemia are the most important risk factors for NAFLD. Due to heavy enrichment with metabolic risk factors, individuals with NAFLD are at significantly higher risk for cardiovascular disease. Individuals with NAFLD have higher incidence of type 2 diabetes. The diagnosis of NAFLD requires imaging evidence of hepatic steatosis in the absence of competing etiologies including significant alcohol consumption. Liver biopsy remains the gold standard for diagnosing NASH and for determining prognosis. Weight loss remains a cornerstone of treatment. Weight loss of ∼5{\%} is believed to improve steatosis, whereas ∼10{\%} weight loss is necessary to improve steatohepatitis. A number of pharmacologic therapies have been investigated to treat NASH, and agents such as vitamin E and thiazolidinediones have shown promise in select patient subgroups.",
keywords = "Fatty liver, Steatohepatitis, Steatosis, Thiazolidinediones",
author = "Howard Masuoka and Naga Chalasani",
year = "2013",
month = "4",
doi = "10.1111/nyas.12016",
language = "English",
volume = "1281",
pages = "106--122",
journal = "Annals of the New York Academy of Sciences",
issn = "0077-8923",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Nonalcoholic fatty liver disease

T2 - An emerging threat to obese and diabetic individuals

AU - Masuoka, Howard

AU - Chalasani, Naga

PY - 2013/4

Y1 - 2013/4

N2 - Nonalcoholic fatty liver disease (NAFLD) is the most common liver disease in the Western world and its incidence is increasing rapidly. NAFLD is a spectrum ranging from simple steatosis, which is relatively benign hepatically, to nonalcoholic steatohepatitis (NASH), which can progress to cirrhosis. Obesity, insulin resistance, type 2 diabetes mellitus, and dyslipidemia are the most important risk factors for NAFLD. Due to heavy enrichment with metabolic risk factors, individuals with NAFLD are at significantly higher risk for cardiovascular disease. Individuals with NAFLD have higher incidence of type 2 diabetes. The diagnosis of NAFLD requires imaging evidence of hepatic steatosis in the absence of competing etiologies including significant alcohol consumption. Liver biopsy remains the gold standard for diagnosing NASH and for determining prognosis. Weight loss remains a cornerstone of treatment. Weight loss of ∼5% is believed to improve steatosis, whereas ∼10% weight loss is necessary to improve steatohepatitis. A number of pharmacologic therapies have been investigated to treat NASH, and agents such as vitamin E and thiazolidinediones have shown promise in select patient subgroups.

AB - Nonalcoholic fatty liver disease (NAFLD) is the most common liver disease in the Western world and its incidence is increasing rapidly. NAFLD is a spectrum ranging from simple steatosis, which is relatively benign hepatically, to nonalcoholic steatohepatitis (NASH), which can progress to cirrhosis. Obesity, insulin resistance, type 2 diabetes mellitus, and dyslipidemia are the most important risk factors for NAFLD. Due to heavy enrichment with metabolic risk factors, individuals with NAFLD are at significantly higher risk for cardiovascular disease. Individuals with NAFLD have higher incidence of type 2 diabetes. The diagnosis of NAFLD requires imaging evidence of hepatic steatosis in the absence of competing etiologies including significant alcohol consumption. Liver biopsy remains the gold standard for diagnosing NASH and for determining prognosis. Weight loss remains a cornerstone of treatment. Weight loss of ∼5% is believed to improve steatosis, whereas ∼10% weight loss is necessary to improve steatohepatitis. A number of pharmacologic therapies have been investigated to treat NASH, and agents such as vitamin E and thiazolidinediones have shown promise in select patient subgroups.

KW - Fatty liver

KW - Steatohepatitis

KW - Steatosis

KW - Thiazolidinediones

UR - http://www.scopus.com/inward/record.url?scp=84875679556&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875679556&partnerID=8YFLogxK

U2 - 10.1111/nyas.12016

DO - 10.1111/nyas.12016

M3 - Article

C2 - 23363012

AN - SCOPUS:84875679556

VL - 1281

SP - 106

EP - 122

JO - Annals of the New York Academy of Sciences

JF - Annals of the New York Academy of Sciences

SN - 0077-8923

IS - 1

ER -